Isatuximab added to other drugs for relapsed myeloma
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This early-phase study tests isatuximab (an anti-cancer antibody) combined with other study medicines in people whose multiple myeloma has come back or not responded. It aims to improve control of the disease after you’ve already had multiple prior treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- Your multiple myeloma has returned or is resistant, and you’ve had at least 2 prior treatment lines for myeloma.
- Your disease must be measurable by lab tests (M protein or related markers in blood/urine).
- Your general health score is ECOG 0–1, meaning you can do most usual activities.
- You can use effective birth control (if you could become pregnant or father a child).
- You can meet key safety lab and organ-function limits (blood counts, kidney function, liver tests, and certain mineral levels).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of drugs (isatuximab, carfilzomib, and dexamethasone) given as shots under the skin for people whose multiple myeloma has come back or stopped responding to treatment. It aims to see if this mix works better than previous options.
This trial tests a new injected drug for people with multiple myeloma that has returned or stopped responding to at least 3 prior treatments. The goal is to see if the drug is safe and works against the cancer.
This trial tests two drugs, elranatamab and isatuximab, given together to people whose multiple myeloma has come back or stopped responding to earlier treatments. The goal is to see if the combination can shrink or control the cancer where other therapies have not worked well.
This Phase 2 study tests a combination of medicines (isatuximab, belantamab mafodotin, pomalidomide, and dexamethasone) for multiple myeloma that has come back or did not respond to prior treatment. It may help by better controlling the myeloma after standard therapies have failed.
This study allows people with multiple myeloma who are already benefiting from the drug isatuximab in an earlier clinical trial to keep receiving it after that trial ends. It is an extension study, meaning you can continue your treatment without interruption.
This trial tests a combination of four drugs (isatuximab, iberdomide, bortezomib, and dexamethasone) for people newly diagnosed with multiple myeloma who are either unable or choose not to have a stem cell transplant. The goal is to see if this combination can effectively control the disease.
Hear when a new Plasma Cell Myeloma Refractory trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.